Automate Your Wheel Strategy on EOLS
With Tiblio's Option Bot, you can configure your own wheel strategy including EOLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EOLS
- Rev/Share 4.2996
- Book/Share -0.289
- PB -21.2454
- Debt/Equity -8.3051
- CurrentRatio 2.274
- ROIC -0.2608
- MktCap 397168473.0
- FreeCF/Share -0.2667
- PFCF -23.0778
- PE -6.392
- Debt/Assets 0.677
- DivYield 0
- ROE 17.9125
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | EOLS | Needham | Buy | Hold | -- | -- | Aug. 6, 2025 |
| Initiation | EOLS | BTIG Research | -- | Buy | -- | $21 | April 17, 2025 |
News
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
Published: September 22, 2025 by: PRNewsWire
Sentiment: Neutral
Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partnership underscores Evolus' commitment to patient safety and provider education for their new FDA-approved filler line.
Read More
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.13 per share a year ago.
Read More
Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Evolus, Inc. (NASDAQ:EOLS ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP, Head of Global IR and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - Leerink Partners Navann Ty - BNP Paribas Serge Belanger - Needham Doug Tsao - H.C. Wainwright Sam Eiber - BTIG Operator Good afternoon, everyone.
Read More
Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Evolus, Inc. (EOLS) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.14 per share a year ago.
Read More
Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
US FDA approves Evolus' anti-wrinkle gels
Published: February 13, 2025 by: Reuters
Sentiment: Positive
Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.
Read More
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection. These approvals mark Evolus' entry into the U.S. HA dermal filler market and solidifies the company's position as a multi-product innovator in aesth.
Read More
About Evolus, Inc. (EOLS)
- IPO Date 2018-02-08
- Website https://www.evolus.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO David Moatazedi
- Employees 372